SUMMARY, EXPLANATION AND LIMITATIONS:
Anti-PNL2 is a useful antibody for the immunohistochemical identification of melanomas and clear cell sarcomas. Busam et al. evaluated the immunoreactivity of PNL2 antibody in comparison with established melanocytic markers like Melan-A/MART-1 (clone A103), Tyrosinase (clone T311), gp100 (clone HMB45) and MiTF (clone D5) on metastatic melanomas. In normal tissue PNL2 stained normal lymphocytes and neutrophile granulocytes but no other cell types. Among melanocytic lesions benign nevi and primary malignant melanomas, especially epithelioid variants thereof, stained positive. Only 1 of 13 desmoplastic melanomas reacted with PNL2. The sensitivity of PNL2 for metastatic melanoma was 87% in this study, whereas sensitivity of Melan-A, HMB45 and MiTF were 82%, 76%, and 84% respectively. Only Tyrosinase with a sensitivity of 92% showed a comparable sensitivity. Non-melanocytic lesions found to be positive with PNL2 include clear cell sarcomas, PEComas, melanotic schwannomas, angiomyolipomas, and CML. Despite its reactivity with granulocytes PNL2 is considered to be a valuable reagent for the diagnosis of melanocytic tumours. In combination with other markers PNL2 can help to reduce the number of IHC-negative metastatic melanomas.
Staining pattern: Cytoplasmic membrane.
Positive control: Tissue sample from melanoma.
This antibody is designed for the specific localization of human antigen melanoma associated PNL2 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
It is useful in identifying melanoma and clear cell carcinomas.